ESTRO 2024 - Abstract Book

S2440

Clinical - Urology

ESTRO 2024

Keywords: Prostate cancer, PET-PSMA

1461

Mini-Oral

Prostate cancer patients with lower muscle mass have increased late toxicities post-radiotherapy.

Alan McWilliam 1,2 , Jane Shortall 1 , Tanuj Puri 1 , Eliana Vasquez Osorio 1,2 , Marcel van Herk 1,2 , Ananya Choudhury 1,2 , Peter Hoskin 1,2 , Sarah Kerns 3 , David Azria 4 , Marie-Pierre Farcy-Jacquet 5 , Jenny Chang-Claude 6 , Alison Dunning 7 , Maarten Lambrecht 8 , Barbara Avuzzi 9 , Dirk de Ruysscher 10 , Petra Seibold 6 , Elena Sperk 11 , Chris Talbot 12 , Adam Webb 12 , Ana Vega 13 , Liv Veldeman 14 , Barry Rosenstein 15 , Catharine West 1 , Donal McSweeney 1 1 Division of Cancer Science, University of Manchester, Manchester, United Kingdom. 2 Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, United Kingdom. 3 Radiation Oncology, Medical College of Wisconsin, Milwaukee, USA. 4 Radiation Oncology, Montpellier Cancer Institute, Montpellier, France. 5 Institut du Cancer Du Gard, CHU Carémeau, nimes, France. 6 German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany. 7 Department of Public Health and Primary Care, The University of Cambridge, Cambridge, United Kingdom. 8 KU Leuven, University of Leuven, Leuven, Belgium. 9 Unit of radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 10 Maastro Clinic, Maastro University, Maastro, Netherlands. 11 Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany. 12 Department of Genetics & Cancer Sciences, University of Leicester, Leicester, United Kingdom. 13 Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Santiago, Spain. 14 Ghent University Hospital, Ghent University, Ghent, Belgium. 15 The Department of Radiation Oncology and the Department of Genetics & Genomic Sciences, Icahn School of Medicine, New York, USA

Purpose/Objective:

Prostate cancer is typically treated with combination therapy, including androgen deprivation therapy (ADT), novel androgen receptor signalling inhibitors, surgery, chemotherapy, and radiotherapy. Each of which may result in treatment related toxicities. Men receiving hormonal treatments will experience a reduction in skeletal muscle and an increase in body fat [1,2]. There is a growing understanding of the importance of body composition on treatment efficacy, with recent pooled analysis of RTOG 0406 and RTOG 0126 illustrating better body composition (increased muscle mass) resulting in improved overall survival [3]. In this abstract, we investigate if baseline body composition influences radiotherapy related toxicities.

Material/Methods:

Data from 1681 men with prostate cancer were available from the multicentre prospective REQUITE study, including the radiotherapy planning CT scan and patient reported outcomes up to two-years post-radiotherapy [4]. An in-house AI tool identified the third lumbar vertebra (L3), where it then segmented the muscle compartment [5].